Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 15/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990791 | 0.81 | EGLN2 (0.45) | EGLN2KDM1ADYRK1AMAP4K4SCN5A | |
| SCHEMBL1997076 | 0.77 | APP (0.41) | DYRK1ASCN5A | |
| SCHEMBL30013771 | 0.76 | EGLN2 (0.58) | EGLN2DYRK1AMAP4K4SCN5A | |
| SCHEMBL17080364 | 0.76 | EGLN2 (0.41) | EGLN2MAP4K4 | |
| SCHEMBL9902614 | 0.75 | SCN5A (0.40) | EGLN2DYRK1ASCN5A | |
| SCHEMBL6322323 | 0.75 | DYRK1A (0.40) | EGLN2DYRK1ASCN5A | |
| SCHEMBL6316118 | 0.75 | GRM5 (0.44) | EGLN2DYRK1ASCN5A | |
| SCHEMBL6315893 | 0.75 | DYRK1A (0.40) | EGLN2KDM1ADYRK1ASCN5A | |
| SCHEMBL4553627 | 0.74 | DYRK1A (0.39) | EGLN2KDM1ADYRK1ASCN5A | |
| SCHEMBL6314221 | 0.72 | EGLN2 (0.43) | EGLN2DYRK1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018217-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-04-28 | — | — | US | claimed |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2015-01-22 | — | — | US | claimed |
| EP-2318394-B1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-01-22 | — | — | EP | claimed |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-05-31 | — | — | US | claimed |
| US-20100016303-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2010-01-21 | — | — | US | claimed |
| WO-2009152825-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| US-20240182492-A1 | AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2024-06-06 | — | — | US | disclosed |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-02-13 | — | — | US | disclosed |
| EP-3795573-B1 | CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3795573-B1 | CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210154192-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016303-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | EGLN2 2987/4885KDM1A 281/4885DYRK1A 1648/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | EGLN2 338/4885KDM1A 2074/4885DYRK1A 3718/4885 |
| US-20210154192-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | KCNJ11, NISCH, CYP4Z1 | EGLN2 490/4885KDM1A 4150/4885DYRK1A 3409/4885 |
| US-20240182492-A1 | AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | EZH2, EED, EZH1 | EGLN2 1645/4885KDM1A 81/4885DYRK1A 2333/4885 |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | TK2, TYMP, DPYD | EGLN2 446/4885KDM1A 2864/4885DYRK1A 1786/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | EGLN2 338/4885KDM1A 2074/4885DYRK1A 3718/4885 |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | EGLN2 2987/4885KDM1A 281/4885DYRK1A 1648/4885 |
| US-20090076070-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | EGLN2 4164/4885KDM1A 3989/4885DYRK1A 3071/4885 |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | EGLN2 2987/4885KDM1A 281/4885DYRK1A 1648/4885 |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | EGLN2 490/4885KDM1A 4150/4885DYRK1A 3409/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | EGLN2 338/4885KDM1A 2074/4885DYRK1A 3718/4885 |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | EGLN2 490/4885KDM1A 4150/4885DYRK1A 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.